Novo Nordisk Cuts Prices on Ozempic and Wegovy Amid Increasing Generic Competition
Novo Nordisk Reduces Prices of Semaglutide Brands in India
Mumbai: Novo Nordisk, a leading innovator in the pharmaceutical industry, has announced a significant price reduction for its semaglutide brands Ozempic and Wegovy in India. The move comes in response to the loss of patent exclusivity for semaglutide on March 20, which triggered a surge in cheaper generics in the market.
According to the company, the starting dose prices for Ozempic and Wegovy will be reduced by 36% and 48%, respectively. The new prices will be effective from April 1. The starting dose for Ozempic (0.25 mg) will be available at ₹1,415 per week or ₹5,660 per month, while the starting dose for Wegovy will be available at ₹1,415 per week or ₹5,660 per month. This represents a significant reduction from the current prices of ₹10,850-₹16,400 per month for Wegovy and ₹8,800-₹11,175 per month for Ozempic.
The price reductions are part of Novo Nordisk's efforts to make its innovative therapies more accessible to a larger section of people living with diabetes and obesity in India. The company has cut prices to make best-in-class cardiometabolic care more affordable for people with type 2 diabetes, overweight, and obesity in India.
| Product | Current Price | New Price | Price Reduction |
|---|---|---|---|
| Ozempic (0.25 mg) | ₹8,800-₹11,175/month | ₹5,660/month | 23.8% |
| Wegovy (0.25 mg) | ₹10,850-₹16,400/month | ₹5,660/month | 27% |
Novo Nordisk is facing intense competition in the Indian market, with several generic makers offering cheaper versions of semaglutide. The company is banking on its innovator edge, with its drug being backed by clinical trials and manufactured using superior rDNA technology. Novo Nordisk is also facing competition from generic makers through aggressive marketing tactics.
In a recent trademark dispute, Novo Nordisk settled with Dr. Reddy's Laboratories after the latter attempted to launch its semaglutide drug under the brand name 'Olymviq', which was phonetically similar to Novo Nordisk's trademark Ozempic.
India is a key market for GLP-1s, with rising obesity rates and diabetes prevalence. According to a 2023 Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study, India has 254 million people with generalized obesity and 351 million with abdominal obesity. Over 101 million people in India are living with type-2 diabetes, according to the study.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
Investor Takeaway
Investors should be cautious of the impact of generic competition on pharmaceutical companies.
More in Market
SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
